HIV/AIDS Clinical Trial
Official title:
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults in the Era of Highly Active Antiretroviral Therapy: Analysis Stratified by CD4 T-cell Count
HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases. Pneumococcal vaccination is the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is still unclear. HIV-infected subjects aged ≥ 18 years were recruited and divided into two age-matched groups: group 1 (subjects with CD4 T-cell counts ≥350 cells/µL) and group 2 (subjects with CD4 T-cell counts <350 cells/µL). Multiplex opsonophagocytic killing assay was used to compare immunogenicity after the immunization of 13-valent pneumococcal conjugate vaccine (PCV13).
This single-center, open-label non-randomized clinical trial was conducted at Korea
University Guro Hospital from April 2015 to January 2017. Based on the CD4 T-cell counts at
the time of study enrollment, HIV-infected subjects aged ≥ 18 years were divided into two
groups, group 1 (subjects with CD4 T-cell counts ≥350 cells/µL) and group 2 (subjects with
CD4 T-cell counts <350 cells/µL).
The primary objective of the study was to demonstrate that the immune responses to PCV13
serotypes in Group 2 (CD4 T-cell counts <350 cells/µL) were not inferior to those in Group 1
(CD4 T-cell counts ≥350 cells/µL) at one month after vaccination. In addition, the safety
profiles of PCV13 were compared between two study groups.
HIV-infected subjects aged ≥ 18 years with stable underlying diseases (≥ 4 weeks on HAART)
were eligible for this study. All available subjects with low CD4 T-cell counts (<350
cells/µL, group 2) were recruited, and age/visit day-matched controls with high CD4 T-cell
counts (≥350 cells/µL, group 1) were enrolled. The exclusion criteria were as follows: 1) a
history of pneumococcal infection within the recent five years, 2) previous pneumococcal
vaccination, 3) current opportunistic infections, 4) known immunodeficiency other than HIV
infection and 5) coagulation disorders.
The study was approved by the ethics committee of Korea University Guro Hospital (IRB No.
2014GR0014) and was conducted in accordance with the Declaration of Helsinki and Good
Clinical Practice. Informed consent was taken for all participants before enrollment. Venous
blood samples of 10 mL were collected on day 0 and post-vaccination day 28 ± 7.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|